ArticleViruses2020
Live Attenuated African Swine Fever Viruses as Ideal Tools to Dissect the Mechanisms Involved in Cross-Protection.
Article in Viruses, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 49 citations in OpenAlex.
- Limited cross-protection induced by live attenuated ASF vaccines emphasizes caution for field use.Emerging microbes & infections · 2026Article
- Hybrid genotype I and II ASFVEmerging microbes & infections · 2026Article
- First detection and characterization of a non-haemadsorbing African swine fever virus (genotype II) isolated from a wild boar in Russia.Frontiers in microbiology · 2026Article
- Evaluation of Cross-Protection of African Swine Fever Vaccine ASFV-G-ΔI177L Between ASFV Biotypes.Vaccines · 2025Article
- The attenuated African swine fever vaccine HLJ/18-7GD provides protection against emerging prevalent genotype II variants in China.Emerging microbes & infections · 2024Article
- Review
- Recent progress on gene-deleted live-attenuated African swine fever virus vaccines.NPJ vaccines · 2024Review
- Brincidofovir is a robust replication inhibitor against African swine fever virusEmerging microbes & infections · 2023Article
- Review
- Highly lethal genotype I and II recombinant African swine fever viruses detected in pigs.Nature communications · 2023Article
- Article
- Article
- Seroimmunotyping of African swine fever virus.Frontiers in microbiology · 2023Article
- Vaccines for African swine fever: an update.Frontiers in microbiology · 2023Review
- Article
- African swine fever control and prevention: an update on vaccine development.Emerging microbes & infections · 2022Review
- Review
- Cross-protection against African swine fever virus upon intranasal vaccination is associated with an adaptive-innate immune crosstalk.PLoS pathogens · 2022Article
- Review of the Pig-Adapted African Swine Fever Viruses in and Outside Africa.Pathogens (Basel, Switzerland) · 2022Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
African swine fever (ASF) has become the major threat for the global swine industry. Furthermore, the epidemiological situation of African swine fever virus (ASFV) in some endemic regions of Sub-Saharan Africa is worse than ever, with multiple virus strains and genotypes currently circulating in a given area. Despite the recent advances on ASF vaccine development, there are no commercial vaccines yet, and most of the promising vaccine prototypes available today have been specifically designed to fight the genotype II strains currently circulating in Europe, Asia, and Oceania. Previous results from our laboratory have demonstrated the ability of BA71∆CD2, a recombinant LAV lacking CD2v, to confer protection against homologous (BA71) and heterologous genotype I (E75) and genotype II (Georgia2007/01) ASFV strains, both belonging to same clade (clade C). Here, we extend these results using BA71∆CD2 as a tool trying to understand ASFV cross-protection, using phylogenetically distant ASFV strains. We first observed that five out of six (83.3%) of the pigs immunized once with 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.